bamzireotide navoxetan (VMT-𝛼-NET) / Perspective Therap, Lantheus - LARVOL DELTA

Cohort level safety and efficacy results for [212Pb]VMT-a-NET in advanced somatostatin receptor subtype 2 (SSTR2+)-expressing neuroendocrine tumors (NETs): Cohorts 1–3 (ESMO 2026) - No abstract available

Clinical • Metastases • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR • SSTR2

Cohort level safety and efficacy results for [212Pb]VMT-alpha-NET in advanced somatostatin receptor subtype 2-expressing neuroendocrine tumors: cohorts 1–3 (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Clinical • Metastases • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR

[212Pb]VMT-α-NET therapy in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs): Dose-limiting toxicity (DLT) observation participants after 1 year follow-up and preliminary report for expansion participants. (ASCO 2025) - P1/2 | "[212Pb]VMT-α-NET is a well-tolerated, next generation RPT showing signs of clinical activity at early dose-levels in this phase 1/2a study. Based on these clinical data, further dose-escalation and development of this promising therapy are warranted."

Endocrine Cancer • Gastrointestinal Disorder • Nephrology • Neuroendocrine Tumor • Oncology • Renal Disease • Solid Tumor • SSTR • SSTR2

[212Pb]VMT-α-NET targeted alpha-particle therapy (TAT) for advanced somatostatin receptor 2-positive (SSTR2+) neuroendocrine tumours (NETs): Mature safety and preliminary efficacy for enrollment from dose-finding cohorts 1 and 2 (n=44) (ESMO 2025) - P1/2 | "Conclusions [ 212 Pb]VMT-α-NET is a well-tolerated, novel, next-generation TAT that demonstrates noteworthy clinical activity at the 185 MBq (5 mCi) dose level. These data justify further clinical development of this promising therapy."

Clinical • Metastases • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR • SSTR2

A Phase 0 Imaging Trial of [203Pb]Pb-VMT-α-NET to Enable Dosimetry and Treatment Planning for Refractory or Relapsed Metastatic Neuroendocrine Tumors with [212Pb]Pb-VMT-α-NET. (PubMed, J Nucl Med) - " [203Pb]Pb-VMT-α-NET appears to be a safe and effective SPECT/CT tracer for imaging NETs larger than 1 cm and for normal organ and tumor radiation dosimetry. The chemically matched 203/212Pb theranostic pair offers the potential for a dosimetry-driven personalized treatment paradigm."

Journal • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR • SSTR2

Perspective Therapeutics, Inc….announced that the European Commission (EC) has granted orphan medicinal product designation for [²¹²Pb]VMT-α-NET for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). (GlobeNewswire) - "The Company is conducting a multi-center, open-label, dose-escalation and dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive tumors who have not received prior radiopharmaceutical therapies...The Company plans to submit additional data for presentation at future medical conferences in 2026-7."

European regulatory • Orphan drug • P1/2 data • Gastrointestinal Neuroendocrine Tumor • Pancreatic Neuroendocrine Tumor

Cohort-level safety and efficacy results for [212Pb]VMT-α-NET in advanced somatostatin receptor subtype 2 (SSTR2+)–expressing neuroendocrine tumors (NETs): Cohorts 1–3. (ASCO 2026) - P1/2 | "Treatment with [212Pb]VMT‑α‑NET continues to demonstrate a favorable safety profile across all treated participants (n = 56) and shows signs of sustained efficacy at the 2.5 mCi and 5 mCi dose levels. The therapy has been well‑tolerated with no observed dose‑limiting toxicities or serious treatment‑related adverse outcomes. Based on these encouraging safety and efficacy findings, the study is ongoing, and enrollment into Cohort 3 (6 mCi) remains active."

Clinical • Metastases • Gastrointestinal Disorder • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR • SSTR2

Predictive dosimetry and dose verification with the 203/212Pb theranostic pair for targeted alpha therapy: feasibility and initial results (SNMMI 2026) - "Our measurements demonstrated that 203Pb enables high quantitative SPECT/CT accuracy and is an ideal imaging surrogate to investigate pharmacokinetics and perform predictive dosimetry of 212Pb-labelled radiopharmaceuticals. 212Pb demonstrated a moderate quantitative SPECT/CT accuracy but with the feasibility of post-treatment dose verification as our initial dose comparison revealed a strong correlation between the calculated pre- and post-treatment doses. This represents significant progress in personalized, image-guided TAT using the 203/212Pb theranostic pair."

Neuroendocrine Tumor • Solid Tumor

Predictive dosimetry and dose verification with the 203/212Pb theranostic pair for targeted alpha therapy: feasibility and initial results (SNMMI 2026) - "Our measurements demonstrated that 203Pb enables high quantitative SPECT/CT accuracy and is an ideal imaging surrogate to investigate pharmacokinetics and perform predictive dosimetry of 212Pb-labelled radiopharmaceuticals. 212Pb demonstrated a moderate quantitative SPECT/CT accuracy but with the feasibility of post-treatment dose verification as our initial dose comparison revealed a strong correlation between the calculated pre- and post-treatment doses. This represents significant progress in personalized, image-guided TAT using the 203/212Pb theranostic pair."

Neuroendocrine Tumor • Solid Tumor

Phase 1, first-in-human clinical trial with [212Pb]VMT-a-NET to treat refractory or relapsed neuroendocrine tumors using forward dosimetric planning with [203Pb]VMT-a-NET SPECT/CT (SNMMI 2026) - P1 | "Trials in Progress"

Clinical • First-in-human • P1 data • Chronic Kidney Disease • Neuroendocrine Tumor • Oncology • Solid Tumor • CST3 • SSTR

Early Phase 1 Safety Results of Pb-212-VMT-alpha-NET in Metastatic or Inoperable Olfactory Neuroblastoma Patients Naïve to Previous Systemic Radionuclide Therapy (SNMMI 2026) - P1 | "While treatment using the beta-emitting Lu-177-DOTATATE has demonstrated some promising clinical efficacy in ONB patients [2], treatment based on theoretically more powerful alpha-emitting radionuclides such as Pb-212 has not been attempted. Early safety results demonstrate that Pb-212-VMT-alpha-NET is well-tolerated in patients with metastatic ONB with no DLTs seen after 2 cycles of treatment and at least 12 weeks after the first administration."

Clinical • Metastases • P1 data • CNS Disorders • Genito-urinary Cancer • Heart Failure • Lung Cancer • Neuroblastoma • Neuroendocrine Tumor • Otorhinolaryngology • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor • SSTR

Predictive dosimetry and dose verification with the 203/212Pb theranostic pair for targeted alpha therapy: feasibility and initial results (SNMMI 2026) - "Our measurements demonstrated that 203Pb enables high quantitative SPECT/CT accuracy and is an ideal imaging surrogate to investigate pharmacokinetics and perform predictive dosimetry of 212Pb-labelled radiopharmaceuticals. 212Pb demonstrated a moderate quantitative SPECT/CT accuracy but with the feasibility of post-treatment dose verification as our initial dose comparison revealed a strong correlation between the calculated pre- and post-treatment doses. This represents significant progress in personalized, image-guided TAT using the 203/212Pb theranostic pair."

Neuroendocrine Tumor • Solid Tumor

Clinical Comparison of Occupational Radiation Dose Exposure from Lu177 Dotatate vs Pb212 VMT alpha NET therapies of Neuroendocrine Tumors (SNMMI 2026) - "Pb212 VMT α NET at clinically active doses results in a significantly lower radiation exposure rate at the end of therapy than the exposure from the standard clinical doses of Lu177 dotatate. The Lu177 dose rate is 47% higher, but less than the approximately 4 fold difference predicted, likely due to the real-world effect of lesser attenuation of the more abundant and energetic Pb212 photons. The lower exposure from Pb212 VMT α NET is of potential practical importance for minimizing staff radiation exposure and for patient release, especially if dose escalation/cycle is contemplated."

Clinical • Neuroendocrine Tumor • Oncology • Solid Tumor

Early Safety Results of Pb-212-VMT-alpha-NET in Metastatic Pheochromocytoma/Paragangliomas or GI-Neuroendocrine Tumors Patients Previously Treated with Lu-177-SSTR Radionuclide Therapy (SNMMI 2026) - P1/2 | "All three patients had 4 cycles each of Lu-177-DOTATATE at 200 mCi prior to enrollment onto the study. Early safety results demonstrate that Pb-212-VMT-alpha-NET is well-tolerated in patients with metastatic PPGL or GI-NET who have been previously treated with Lu-177 based radionuclide therapy, with no DLTs seen in the first 3 patients treated with 2.5 mCi of the agent."

Clinical • First-in-human • Metastases • Alopecia • Gastrointestinal Neuroendocrine Tumor • Hematological Disorders • Immunology • Musculoskeletal Diseases • Musculoskeletal Pain • Neuroendocrine Tumor • Neutropenia • Oncology • Solid Tumor • SSTR

[212Pb]VMT-a-NET in advanced SSTR2+ neuroendocrine tumors: safety and preliminary efficacy results from dose-finding cohorts 1,2 and 3 (AACR 2026) - P1/2 | "Treatment with [212Pb]VMT-α-NET continues to be well-tolerated among all patients treated (n=56), and to show promising efficacy at the dose levels of 2.5 mCi and 5 mCi. The study is ongoing with Cohort 3 (6 mCi) currently open for enrollment."

Clinical • Metastases • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR • SSTR2

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting (The Manila Times) - "Safety update presented on all 64 patients who received at least one treatment and updated efficacy analysis presented on the two patients in Cohort 1 and 23 patients in Cohort 2; Objective response in 43% (10 out of 23) of patients in first half of Cohort 2, including an additional new response and confirmation of the initial response reported at ASCO-GI 2026....Initial efficacy data from additional 23 patients in Cohort 2 and first eight patients in Cohort 3 expected later this year; On track to submit a robust clinical evidence package for presentation to more medical conferences and for regulatory engagement in 2026."

P1/2 data • Neuroendocrine Tumor

Safety and preliminary efficacy results of [212Pb]VMT-a-NET in advanced somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors (NETs). (ASCO-GI 2026) - P1/2 | "[212Pb]VMT-a-NET showed a favorable safety profile and promising clinical benefit for patients with advanced SSTR2-expressing NETs treated at the dose levels of 92.5 MBq and 185 MBq. The study is ongoing with Cohort 3 (222 MBq) currently open for enrollment."

Clinical • Metastases • Gastrointestinal Cancer • Oncology • Solid Tumor • SSTR • SSTR2

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire) - "Updated efficacy analysis suggests durable disease control and deepening of tumor response per RECIST v1.1 in the first 23 patients in Cohort 2 and both patients in Cohort 1; Objective response in 39% of patients in Cohort 2 regardless of SSTR2 expression profile, including one Cohort 2 patient who experienced an initial objective response pending confirmation since the prior update, and 8 previously reported confirmed responders; Cohort 3 (6.0 mCi) dose limiting toxicities (DLT) assessment completed as planned; cleared to treat more patients with one additional patient already treated."

P1/2 data • Neuroendocrine Tumor

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)

P1/2 data • Neuroendocrine Tumor

Clinical Experience with Targeted Alpha-Emitter Peptide Receptor Radionuclide Therapy (α-PRRT) for Somatostatin Receptor-Positive Neuroendocrine Tumors. (PubMed, Pharmaceuticals (Basel)) - "Early results support α-PRRT as a potential first- or second-line therapeutic option. Ongoing phase III trials will be critical to confirm its long-term safety, survival outcomes, and role in routine clinical practice."

Journal • Review • Gastrointestinal Disorder • Hematological Disorders • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR

Clinical Highlights: VMT-α-NET (GlobeNewswire) - "Among the 16 patients with SSTR2 expression in all of their tumors, seven (44%) achieved confirmed responses, and 14 (87.5%) remained progression-free and on study, with a median follow-up of 41 weeks. Initial anti-tumor activity data for an additional 23 patients in Cohort 2 and eight patients in Cohort 3 are expected to be submitted for presentation at a future medical conference in 2026."

P1/2 data • Neuroendocrine Tumor • Pancreatic Cancer • Paraganglioma • Pheochromocytoma

[212Pb]VMT-a-NET for somatostatin receptor subtype 2 (SSTR2)-expressing tumors: safety and preliminary efficacy results in patients with advanced neuroendocrine tumors (NETs) (AACR-NCI-EORTC 2025) - P1/2 | "[212Pb]VMT-a-NET showed a favorable safety profile and promising clinical benefit for patients with advanced SSTR2-expressing NETs treated at the dose level of 185 MBq (5 mCi). The study is ongoing with cohort 3 currently open for enrollment."

Clinical • Metastases • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR • SSTR2

[212Pb]VMT-alpha-NET for advanced SSTR+ NETs: safety and preliminary efficacy results from cohorts 1 and 2 of the dose escalation phase (NANETS 2025) - P1/2 | "CONCLUSIONS [212Pb]VMT-alpha-NET is a well-tolerated therapy for patients with advanced NETs, and it has shown promising clinical benefit at the dose level of 185 MBq [5 mCi]. The study is ongoing and open for enrollment in cohort 3."

Clinical • Metastases • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR • SSTR2

Perspective Therapeutics Provides Recent Business Highlights… (GlobeNewswire) - "Four of the initial seven patients enrolled in Cohort 2 experienced objective responses as defined by RECIST v1.1. Three of those patients experienced confirmed response and remained in response. One new first response was subject to confirmation. Seven of nine patients in Cohorts 1 and 2 remained free from disease progression after more than one year of follow-up."

P1/2 data • Neuroendocrine Tumor

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting

Enrollment open • Genito-urinary Cancer • Head and Neck Cancer • Kidney Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor